For pediatric and elderly patients, conditions related to impaired swallowing, and for when compliance may be difficult effective fast dissolve dose forms deliver solutions.

1. Help Overcome Compliance Challenges with Fast Dissolve Technology
Zydis® Fast Dissolve ODT disperses up to 10x faster thanalternatives meeting patient, therapeutic and payer needs. For paediatric and elderly patients, conditions related to impaired swallowing, and for when compliance may be difficulteffective fast dissolve dose forms deliver solutions.
Many people suffer from swallowing difficulties and dysphagia is a particularly common problem for patients who have Parkinson’s disease. Zydis fast dissolve formulation for Zelapar (Selegiline anti-Parkinson’s compound) had a positive impact for patients by reducing the number and frequency of doses over traditional tablets as well as reducing side effects.
Catalent Japan launched a Zydis non-GMP Laboratory at its Kakegawa softgel facility last month. This new laboratory will deliver proof-of-concept and feasibility studies to customers in the world’s largest Orally Disintegrating Tablet market – Japan. Japan’s elderly population continues to grow; therefore, ODT’s are increasing in demand. Currently, eight Zydis products are imported from Catalent’s Swindon (UK) site.
Best-in-class Family of Fast-Dissolve Technologies
Zydis ODT • Unique, freeze-dried oral solid dosage • Instant oral dispersion - typically less than 3 seconds Zydis Ultra • Further enhanced Fast-Dissolve formulations • Greater taste masking capabilities; increased doses Zydis Granules • Highest dose and more taste masking options ZydisBio • Further enhanced Fast-Dissolve formulations • Allergens; Peptides & Proteins; Viral Vaccines
Better Teatments with Fast-Dissolve Technologies • Improved bioavailability • Increased speed of onset • Enhanced patient compliance & convenience • Buccal / sublingual absorption • Safety profile improvements Build Leading Brands • In market brand performance • Brand differentiation See how Zydis enabled brands have transformed market performance and helped improve patient outcomes.

2. Catalent's Kakegawa Facility - New Enhancements to Softgel Capabilities
Catalent’s Kakegawa facility recently expanded its seamless softgels productioncapacity. Our dedication to innovation has allowed the expansion in processing techniques to include OptiGel™ Micro Technology. This technology has numerous advantages that can help bring your compounds to market. OptiGel™ Micro Technology is ideal for patient populations where swallowing may pose difficulty such as pediatric, geriatric, oncology, etc. Learn more here.
Every molecule has a challenge. We have a solution.
or call +1 888 SOLUTION (7658846) to speak with one of our experts today!
To unsubscribe or manage your subscriptions, please click here. Global: For more information call +1-866-720-3148, Email us at sales@catalent.com, or visit www.catalent.com Europe: For more information call 00800 88 55 6178, Email us at sales@catalent.com, or visit www.catalent.com Catalent Pharma Solutions respects your privacy. ©Copyright 2014, Catalent Pharma Solutions, Inc. 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved.